NECLIFE
Nectar Lifesciences Limited (NECLIFE) Stock Analysis
Nectar Lifesciences Limited is an Indian pharmaceutical company manufacturing cephalosporin APIs and formulations for domestic and regulated markets. It has faced restructuring and debt challenges while operating antibiotic facilities. Performance depends on API prices and compliance remediation. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹10.10
-0.98% 1W | -24.90% 52W
Market Cap
197 CR
P/E Ratio
28.9
52W High
₹22.4
52W Low
₹9.3
Div. Yield
0%
Beta
0.7
50 DMA
₹11.1
200 DMA
₹12.2
Profit Margin
0%
Inst. Own.
0%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 394 | 398 | 452 | 441 | 359 | 6 | 0 | 0 | 5 | 1 | 0 | 1 | 0 |
| Expenses | 359 | 371 | 410 | 393 | 319 | 6 | 0 | 0 | 6 | 0 | 2 | 59 | 28 |
| Operating Profit | 36 | 27 | 42 | 48 | 40 | -1 | -0 | -0 | -1 | 1 | -2 | -57 | -27 |
| OPM % | 9% | 7% | 9% | 11% | 11% | -10% | -500% | -500% | -16% | 77% | -4,437% | -6,198% | |
| Other Income | 0 | 11 | 0 | 1 | 1 | 7 | 8 | -130 | -62 | -176 | 35 | -24 | 3 |
| Interest | 18 | 21 | 25 | 24 | 20 | 0 | 0 | 0 | 0 | 0 | 30 | 6 | 0 |
| Depreciation | 15 | 15 | 15 | 15 | 15 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit before tax | 3 | 2 | 2 | 11 | 5 | 5 | 8 | -130 | -64 | -176 | 3 | -88 | -24 |
| Tax % | 41% | 38% | 36% | 95% | 40% | -2% | 2% | -0% | -1% | 0% | -339% | -22% | -37% |
| Net Profit | 2 | 1 | 2 | 1 | 3 | 6 | 8 | -130 | -63 | -176 | 14 | -68 | -15 |
| EPS in Rs | 0.08 | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | -5.80 | -2.82 | -7.85 | 0.64 | -3.50 | -0.79 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,638 | 1,674 | 1,635 | 1,874 | 2,779 | 2,363 | 1,541 | 1,665 | 1,520 | 1,682 | 1,664 | 0 | 2 |
| Expenses | 1,371 | 1,436 | 1,411 | 1,638 | 2,514 | 2,143 | 1,432 | 1,507 | 1,467 | 1,530 | 1,694 | 8 | 88 |
| Operating Profit | 267 | 239 | 224 | 236 | 264 | 220 | 109 | 159 | 53 | 152 | -30 | -8 | -86 |
| OPM % | 16% | 14% | 14% | 13% | 10% | 9% | 7% | 10% | 3.5% | 9% | -1.8% | -2,920% | -3,520% |
| Other Income | 20 | 6 | 23 | 6 | 6 | 4 | -22 | 11 | 43 | 15 | 5 | -279 | -162 |
| Interest | 126 | 123 | 117 | 115 | 148 | 126 | 112 | 79 | 79 | 87 | 75 | 36 | 36 |
| Depreciation | 77 | 57 | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 62 | 0 | 0 |
| Profit before tax | 85 | 64 | 67 | 63 | 59 | 37 | -85 | 34 | -42 | 18 | -162 | -323 | -285 |
| Tax % | 22% | 15% | 18% | 17% | 19% | 15% | -14% | 26% | -43% | 73% | -30% | -9% | |
| Net Profit | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 5 | -114 | -293 | -245 |
| EPS in Rs | 2.95 | 2.42 | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 | -15.08 | -11.50 |
| Dividend Payout % | 3% | 4% | 2% | 2% | 2% | 4% | 0% | 0% | 0% | 0% | 0% | 0% |
Shareholding Pattern
Promoters44.53%
FIIs0.82%
DIIs0.19%
Public54.45%
Promoters44.91%
FIIs0.62%
DIIs0.08%
Public54.37%
Promoters44.91%
FIIs0.52%
Public48.73%
Promoters51.84%
FIIs0.60%
DIIs0.01%
Public43.52%
Promoters51.84%
FIIs0.50%
DIIs0.01%
Public43.90%
Promoters55.80%
FIIs16.07%
Public28.12%
Promoters55.80%
FIIs16.98%
Public27.20%
Promoters44.53%
FIIs1.65%
DIIs0.15%
Public53.64%
Promoters51.84%
FIIs0.60%
DIIs0.01%
Public43.52%
Promoters51.84%
FIIs0.50%
DIIs0.01%
Public43.90%
NECLIFE
Holdings Analysis
Key strengths & risk signals
46
Overall
34
Fundamental
59
Technical
Risks (4)
LOW MARGIN! 0% profit margin - thin profits.
POOR YEAR! Stock declined 24.9% in the last year.
WEAK POSITION! Current price (10.1) is below both moving averages.
WEAK! Trading at 6.1% of 52W range - near yearly lows.
Strengths (3)
BULLISH SENTIMENT! In last 30 days: 9 up days, 21 down days. Avg volume on up days: 310,392 vs down days: 160,504. Ratio: 1.93x
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.
APPROACHING OVERSOLD! RSI at 36.0 - watch for reversal.
Fundamental & Technical Analysis
46Overall
34Fundamental
59Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: 0% (DECLINING, 2/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
0/10
LOW MARGIN! 0% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 28.18% public ownership - balanced ownership structure.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (11.1) is below 200-day average (12.2) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (10.1) is below both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
1/10
POOR YEAR! Stock declined 24.9% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 9 up days, 21 down days. Avg volume on up days: 310,392 vs down days: 160,504. Ratio: 1.93x
RSI
4/5
APPROACHING OVERSOLD! RSI at 36.0 - watch for reversal.
52W Range
1/5
WEAK! Trading at 6.1% of 52W range - near yearly lows.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 1.0% (1 week), 15.4% (1 month), 9.5% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NECLIFE | ₹10.10 | 28.9 | – | – | – | -24.9% | 46 | BREAKDOWN | -75.6% | -77.3% | – | – |
| MEDICO | ₹22.80 | 13.7 | 5.8% | 13.8% | 21.9% | -55.7% | 55 | BREAKDOWN | +38.9% | -57.6% | +81.2% | +22.2% |
| BROOKS | ₹70.10 | 15.6 | 15.9% | 11.0% | – | -52.9% | 62 | BREAKOUT | -118.8% | -220.0% | -9.8% | +13.9% |
| NATCAPSUQ | ₹160.00 | – | -8.1% | 3.6% | – | -32.4% | 46 | BREAKDOWN | +1.8% | +14.0% | +7.7% | -16.8% |
| BALPHARMA | ₹93.10 | 20.5 | 2.2% | 0.1% | 34.7% | +18.7% | 66 | CONSOLIDATING UP | +450.0% | -69.4% | +34.4% | +5.4% |
| PAR | ₹117.10 | 11 | 13.3% | 11.0% | 1.0% | +21.6% | 66 | BREAKDOWN | +42.7% | +423.3% | +20.3% | +59.6% |
| BALAXI | ₹22.30 | 49.6 | 0.5% | -7.1% | -68.6% | -48.5% | 51 | APPROACHING SUPPORT | +333.3% | +116.7% | +14.1% | +14.1% |
| KREBSBIO | ₹56.00 | – | -55.9% | -23.1% | – | -16.8% | 47 | BREAKDOWN | -52.8% | +8.7% | +27.3% | +2.9% |
Data from TradeAlone · Updated daily
No news tagged for NECLIFE yet.
